Logo Image
NP/PA Connect
News
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference ListingNP/PA Conferences
Events
NP/PA EventsCase-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
Awareness SpotlightInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Watch
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Anti-Aging
  • Artificial Intelligence
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hair & Scalp
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Spotlight -
NP/PA Connect|
Acne|
Atopic Dermatitis|
Chronic Hand Eczema|
Chronic Spontaneous Urticaria|
Drug Watch|
Hidradenitis Suppurativa|
Psoriasis|
Skin Cancer|
Vitiligo
Advertisement

Richard Payerchin

Advertisement

Articles by Richard Payerchin

Study: Facebook Policy Blocked Vaccine Misinformation

ByRichard Payerchin
March 4th 2022

Social media a ‘critical challenge for public health.'

Teladoc, Amazon Announce Partnership for Telehealth through Echo devices

ByRichard Payerchin
March 3rd 2022

'Alexa, I want to talk to a doctor’

Study: Medicare Advantage Posts Banner Year in 2022

ByRichard Payerchin
March 1st 2022

Medicare Advantage program enrollment grows 9 percent for 2022.

  • Prev
  • 1
  • 2
  • Prev
Advertisement


Advertisement
Advertisement

Trending on Dermatology Times

1

Dermatology Times Monthly FDA and Pipeline Review: October 2026

2

Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis

3

Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year

4

Updated HS Guidelines Emphasize Biologics and Early Intervention

5

Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us